A larger proportion of non-adherent screening women were HER2-negative (SD = 0.20) and a smaller proportion had unknown HER2 receptor status (SD = 0.21), but there was a similar proportion of women with HER2-positive cancers regardless of compliance (SD < 0.1) (Table 1). The gene discussed is ERBB2; the disease is cancer.